# A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Source: https://onco.cc/trials/nct05885464/  
OnCo record `nct05885464` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BEAM-201 in non-Hodgkin lymphoma, run by Beam Therapeutics Inc., active and no longer recruiting.

## Summary

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) is a phase 1/2 interventional study registered as NCT05885464 by Beam Therapeutics Inc., with 5 participants enrolled, started 2023-05-25 and due to reach its primary completion in 2026-12. Interventions recorded: BEAM-201.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05885464
- Phase: 1/2
- Setting: A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
- Sponsor: Beam Therapeutics Inc.
- Enrolled: 5

## Sources

- ClinicalTrials.gov NCT05885464: https://clinicaltrials.gov/study/NCT05885464

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct05885464.json